September 2025
The PSNZ Neurodevelopment Clinical Network has submitted feedback supporting PHARMAC's proposal to fund Methylphenidate Sandoz XR from December 1, 2025.
Our clinical network believes this additional methylphenidate option will help address ongoing supply shortages and provide prescribers with greater flexibility in managing ADHD treatment.
Our full submission is attached.
More information is available on the PHARMAC website.